The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Hagop Kantarjian to receive Karnofsky Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Hagop Kantarjian will be awarded the American Society of Clinical Oncology’s 2023 David A. Karnofsky Memorial Award for his contributions to leukemia clinical research and his dedication to improving the lives of patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
By Claire Marie Porter
In Brief

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”
PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
By Katie Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account